Ovulation induction with urinary FSH or recombinant FSH in polycystic ovary syndrome patients: A prospective randomized analysis of cost-effectiveness

Reproductive BioMedicine Online

Volumn 9, Issue 5, 2004, Pages 494-499

  Gerli, Sandro ^a   Casini, Maria Luisa ^b   Unfer, Vittorio ^c   Costabile, Loredana ^c   Mignosa, Marcella ^a   Di Renzo, Gian Carlo ^a  

^a UNIVERSITY OF PERUGIA   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

^c AGUNCO Obstetrics and Gynecology Centre   (Italy)

Author keywords

Cost effectiveness; Intrauterine insemination; Ovarian stimulation; PCOS; Recombinant FSH; Urinary FSH

Indexed keywords

CHORIONIC GONADOTROPIN; PROFASI HP; RECOMBINANT FOLLITROPIN; UROFOLLITROPIN;

ADULT; ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DRUG SAFETY; FEMALE; FEMALE INFERTILITY; HUMAN; INTRAUTERINE INSEMINATION; MAJOR CLINICAL STUDY; MULTIPLE PREGNANCY; OVARY CYCLE; OVARY FOLLICLE MATURATION; OVARY HYPERSTIMULATION; OVARY POLYCYSTIC DISEASE; OVULATION INDUCTION; PREGNANCY RATE; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SPONTANEOUS ABORTION; STATISTICAL SIGNIFICANCE; TREATMENT OUTCOME;

EID: 8744310033     PISSN: 14726483     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1472-6483(10)61632-X     Document Type: Article

References (35)

1. Agrawal R, Holmes J, Jacobs HS 2000 Follicle-stimulating hormone or human menopausal gonadotrophin for ovarian stimulation in in vitro fertilization cycles: a meta-analysis. Fertility and Sterility 73, 338-343.
2. Al-Inany H, Aboulghar M, Mansour R, Serour G 2003 Models of cost-effectiveness of recombinant FSH versus urinary FSH. Human Reproduction 18, 305-313.
3. Azziz R 2004 PCOS: a diagnostic challenge. Reproductive BioMedicine Online 8, 644-648.
4. Carmina E, Lobo RA 1999 Polycystic ovary syndrome (PCOS): arguably the most common endocrinopathy is associated with significant morbidity in women. Journal of Clinical Endocrinology and Metabolism 84, 1897-1899.
5. Dale PO, Tanbo T, Haug E, Abyholm T 1998 The impact of insulin resistance on the outcome of ovulation induction with low-dose follicle stimulating hormone in women with polycystic ovary syndrome. Human Reproduction 13, 567-570.
6. Daya S and Gunby J 1999 Recombinant versus urinary follicle stimulating hormone for ovarian stimulation in assisted reproduction. Human Reproduction 14, 2207-2215.
7. Daya S, Gunby J, Hughes EG, Collins JA, Sagle MA 1995. Follicle-stimulating hormone versus human menopausal gonadotrophin for in vitro fertilization cycles: a meta-analysis. Fertility and Sterility 64, 77-86.
8. Daya S, Ledger W, Auray JP et al. 2001 Cost-effectiveness modelling of recombinant FSH versus urinary FSH in assisted reproduction techniques in the UK. Human Reproduction 16, 2563-2569.
9. Diamanti-Kandarakis E, Kouli RC, Bergiele TA et al. 1999 A survey of the polycystic ovary syndrome in the Greek island of Lesbos: hormonal and metabolic profile. Journal of Clinical Endocrinology and Metabolism 84, 4006-4011.
10. Farhi J, West C, Patel A, Jacobs HS 1996 Treatment of anovulatory infertility: the problem of multiple pregnancy. Human Reproduction 11, 429-434.
11. Filicori M, Cognigni GE, Taraborrelli S et al. 2001 Luteinizing hormone activity in menotropins optimizes folliculogenesis and treatment in controlled ovarian stimulation. Journal of Clinical Endocrinology and Metabolism 86, 337-343.
12. Gerli S, Perino M, Abate A et al. 1999 Ovarian stimulation using a new form urinary FSH highly purified: a prospective randomized clinical study. Clinical and Experimental Obstetric and Gynaecology 26, 93-94.
13. Gleicher N and Karande V 2000 Generic human menopausal gonadotrophin (hMG) in place of more costly follicle-stimulating hormone (FSH) for routine ovulation induction. Journal of Assisted Reproduction and Genetics 17, 489-495.
14. Gordon UD, Harrison RF, Fawzy M, Hermelly B, Gordon AC 2001 A randomized prospective assessor-blind evaluation of luteinizing hormone dosage and in vitro fertilization outcome. Fertility and Sterility 75, 324-331.
15. Goverde AJ, McDonnell J, Vermeiden JPW et al. 2000 Intrauterine insemination or in-vitro fertilisation in idiopathic subfertility and male subfertility: a randomized trial and cost-effectiveness analysis. Lancet 355, 13-18.
16. Guzick DS, Sullivan MW, Adamson GD et al. 1998 Efficacy of treatment for unexplained infertility. Fertility and Sterility 70, 207-213.
17. Homburg R 1998 Adverse effects of luteinizing hormone on fertility: fact or fantasy. Baillieres in Clinical Obstetrics and Gynaecology 12, 555-563.
18. Homburg R 2003 The management of infertility associated with polycystic ovary syndrome. Reproductive Biology and Endocrinology 14, 109.
19. Hoomans EHM, Andersen AN, Loft A et al. 1999 A prospective, randomized clinical trial comparing 150 IU recombinant follicle stimulating hormone (Puregon) and 225 IU highly purified urinary follicle stimulating hormone (Metrodin-HP) in a fixed dose regimen in women undergoing ovarian stimulation. Human Reproduction 14, 2442-2447.
20. Hughes EG 1997. The effectiveness of ovulation induction and intrauterine insemination in the treatment of persistent infertility: a meta-analysis. Human Reproduction 12, 1865-1872.
21. Jakubowicz DJ, Nestler JE 1997 17 alpha-Hydroxyprogesterone responses to leuprolide and serum androgens in obese women with and without polycystic ovary syndrome offer dietary weight loss. Journal of Clinical Endocrinology and Metabolism 82, 556-560.
22. L'Informatore Farmaceutico 2001 The Italian Formulary. 61ma edizione, OEMF Editore, Italy.
23. Nestler JE, Jakubowicz DJ, Evans WS, Pasquali R 1998 Effects of metformin on spontaneous and clomiphene-induced ovulation in the polycystic ovary syndrome. New England Journal of Medicine 338 1876-1880.
24. Ola B, Afnan M, Sharif K et al. 2001 Cost-effectiveness of recombinant versus urinary follicle stimulating hormone; whose point of view? Acta Obstetrica and Gynecologica Scandinavica 80, 1141-1142.
25. Out HJ, Mannaerts BMJL, Driessen SGAJ, Coelingh-Bennink HJT 1995. A prospective, randomized, assessor-blind, multicentre study comparing recombinant and urinary follicle stimulating hormone (Puregon® versus Metrodin®) in in-vitro fertilization. Human Reproduction 10, 2534-2540.
26. Royal College of Obstetricians and Gynaecologists 1999 Evidence-based Clinical Guidelines. Guideline Summary No. 3: the management of infertility in secondary care. British Journal of Urology 83, 641-645.
27. Seibel MM, Kamrava MM, McArdle C, Taymor ML 1984 Treatment of polycystic ovary disease with chronic low-dose follicle stimulating hormone: biochemical changes and ultrasound correlation. International Journal of Fertility 29, 39-43.
28. Silverberg K, Daya S, Auray JP et al. 2002 Analysis of the cost effectiveness of recombinant versus urinary follicle-stimulating hormone in in vitro fertilization/intracytoplasmic sperm injection programs in the United States. Fertility and Sterility 77, 107-113.
29. Sovino H, Sir-Petermann T, Devoto L 2002 Clomiphene citrate and ovulation induction. Reproductive BioMedicine Online 4, 303-310.
30. Stanger JD and Yovich JL 1985 Reduced in vitro fertilization of human oocytes from patients with raised basal luteinizing hormone levels during the follicular phase. British Journal of Obstetrics and Gynaecology 92, 385-392.
31. Sykes D, Out HJ, Palmer SJ, van Loon J 2001 The cost-effectiveness of IVF in the UK: a comparison of three gonadotrophin treatments. Human Reproduction 16, 2557-2562.
32. Templeton A and Morris JK 1998 Reducing the risk of multiple births by transfer of two embryos after in vitro fertilization. New England Journal of Medicine 339, 573-577.
33. World Health Organization 1992 WHO Laboratory Manual for the Examination of Human Semen and Semen Cervical Mucus Interaction 3rd edn. Cambridge University Press, Cambridge.
34. Yarali H, Zeyneloglu HB 2004 Gonadotrophin treatment in patients with polycystic ovary syndrome. Reproductive BioMedicine Online 8, 528-537.
35. Yarali H, Bukulmez O, Gurgan T 1999 Urinary follicle-stimulating hormone (FSH) versus recombinant FSH in clomiphene citrate-resistant, normogonadotrophic, chronic anovulation: a prospective randomized study. Fertility and Sterility 72, 276-281.